Vivax Reports

Following the success of the Primaquine Efficacy, Safety and Tolerability Study Group in investigating the effect of primaquine mg/kg dose on efficacy, safety and tolerability of patients with uncomplicated P. vivax, national malaria control programs requested additional local data to better understand the effect of primaquine dose for their local context. This led to the development of automated region and country reports that provide an overview of the clinical efficacy study data available for different regions and countries and summarise the local efficacy, safety and tolerability. These automated reports will be updated every six months as the living systematic review of vivax efficacy studies is updated and investigators are contacted to share their data. 

The reports were coded by Peta Edler from the University of Melbourne with support from Rob Commons and Megha Rajasekhar. Analyses for these reports were based on statistical analysis plans developed for the Primaquine Efficacy, Safety and Tolerability Study Group. For further information, please contact Rob Commons on email: rob.commons@wwarn.org.